Developing new treatments for neurological disorders with better precision, increased efficacy and fewer side effects
Information to shareholders regarding the distribution of CombiGene Vet AB
June 28, 2016
Link to document >> (Only in Swedish)
CombiGene Vet AB’s preferred name change to Panion Animal Health AB has unfortunately been rejected by the Swedish Companies Registration Office, and as a consequence the record date for the distribution has been postponed. A new record date will be announced by CombiGene AB.
A new and extended strategy for CombiGene Vet AB is also announced in this press release. The new strategy means that – in addition to developing and commercializing the canine application if CombiGene’s epilepsy gene therapy – other, similar development projects or late stage products will be in-licensed or acquired for the animal health field.
Read more >>